Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Director
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 9 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Kidney Metabolic

Heart Failure
30th Annual Meeting of the ISCP
Author(s): Maki Komiyama Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
hsCRP Improves CV Risk Prediction in Primary Prevention
Added: 1 month ago Source:  Radcliffe CVRM
High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, has a debated role in primary cardiovascular (CV) prevention. A large, population-based study using UK Biobank data has provided further insight into its utility as a clinical biomarker for identifying individuals at residual risk who do not have known atherosclerotic cardiovascular disease (ASCVD).¹MethodologyThis population… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
SOUL: Oral Semaglutide Improves CV Risk Factors in T2D
Added: 3 weeks ago Source:  Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse… View more

Cardiovascular Kidney Metabolic

Heart Failure
SOUL: Oral Semaglutide Aids CV Risk in T2D
Added: 1 month ago Source:  Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Ramzi Y J Khamis
Job title: Professor of Cardiology, Wu Family Endowed Chair of Cardiology, Consultant Interventional Cardiologist
Prof Ramzi Y. J. Khamis is the Wu Family Endowed Chair of Cardiology at Imperial College London and Consultant Interventional Cardiologist at Imperial College Healthcare NHS Trust, where he leads the High-Risk Atherosclerosis and Cardio-Immune Clinic. He previously served as Clinical Director of Cardiology and Cardiothoracic Surgery at the Trust.His clinical expertise lies in interventional… View more
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
ECG in Severe COVID-19 Infection
Author(s): Kapil Rajendran , Baiju Rajan , Sivaprasad Kunjukrishnapilla , et al Added: 1 year ago

Imaging & Diagnostics

Electrophysiology & Arrhythmia
Apabetalone: Evidence and Outcomes Related to Cardiovascular Health
Author(s): Yimeng Zhang , Nimai Desai , Derek Connolly Added: 1 year ago

Prevention & Chronic Conditions

CV Disease in Special Populations